Vor Biopharma Inc.

NasdaqGS:VOR 주식 보고서

시가총액: US$54.3m

Vor Biopharma 관리

관리 기준 확인 3/4

Vor Biopharma CEO는 Robert Ang, Aug2019 에 임명되었습니다 의 임기는 5.25 년입니다. 총 연간 보상은 $ 2.69M, 22.5% 로 구성됩니다. 22.5% 급여 및 77.5% 보너스(회사 주식 및 옵션 포함). 는 $ 468.62K 가치에 해당하는 회사 주식의 0.86% 직접 소유합니다. 468.62K. 경영진과 이사회의 평균 재임 기간은 각각 2.1 년과 4.3 년입니다.

주요 정보

Robert Ang

최고 경영자

US$2.7m

총 보상

CEO 급여 비율22.5%
CEO 임기5.3yrs
CEO 소유권0.9%
경영진 평균 재임 기간2.1yrs
이사회 평균 재임 기간4.3yrs

최근 관리 업데이트

Recent updates

Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely

Sep 10
Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely

We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

May 24
We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation

Dec 05
Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation

Will Vor Biopharma (NASDAQ:VOR) Spend Its Cash Wisely?

Aug 18
Will Vor Biopharma (NASDAQ:VOR) Spend Its Cash Wisely?

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

May 05
Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Is Vor Biopharma Inc. (NASDAQ:VOR) Trading At A 49% Discount?

Mar 13
Is Vor Biopharma Inc. (NASDAQ:VOR) Trading At A 49% Discount?

We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully

Oct 19
We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully

Vor Bio appoints Eyal C. Attar as chief medical officer

Oct 12

Is Vor Biopharma (NASDAQ:VOR) In A Good Position To Invest In Growth?

Jun 18
Is Vor Biopharma (NASDAQ:VOR) In A Good Position To Invest In Growth?

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Mar 05
Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Aug 30
Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Vor Biopharma: Targeted Therapies For Transplants

Jun 30

We're Not Very Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

May 10
We're Not Very Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

Vor Biopharma EPS misses by $0.03

May 06

CEO 보상 분석

Robert Ang 의 보수는 Vor Biopharma 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

-US$112m

Jun 30 2024n/an/a

-US$118m

Mar 31 2024n/an/a

-US$120m

Dec 31 2023US$3mUS$606k

-US$118m

Sep 30 2023n/an/a

-US$116m

Jun 30 2023n/an/a

-US$106m

Mar 31 2023n/an/a

-US$98m

Dec 31 2022US$5mUS$570k

-US$92m

Sep 30 2022n/an/a

-US$86m

Jun 30 2022n/an/a

-US$81m

Mar 31 2022n/an/a

-US$78m

Dec 31 2021US$2mUS$508k

-US$70m

Sep 30 2021n/an/a

-US$70m

Jun 30 2021n/an/a

-US$65m

Mar 31 2021n/an/a

-US$56m

Dec 31 2020US$3mUS$424k

-US$49m

보상 대 시장: Robert 의 총 보상 ($USD 2.69M )은 US 시장( $USD 649.63K ).

보상과 수익: Robert 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.


CEO

Robert Ang (49 yo)

5.3yrs

테뉴어

US$2,691,044

보상

Dr. Robert Ang, MBBS, MBA, M.D., serves as Independent Non-Executive Director at Enara Bio Limited since September 2021 and serves as its Chairman since August 2024. He is the President, Chief Executive Of...


리더십 팀

이름위치테뉴어보상소유권
Robert Ang
President5.3yrsUS$2.69m0.86%
$ 468.6k
Tirtha Chakraborty
Chief Scientific Officer4yrsUS$1.31m0.14%
$ 78.5k
Eyal Attar
Chief Medical Officer2.1yrsUS$1.40m0.015%
$ 8.2k
Siddhartha Mukherjee
Scientific Founder & Chairman of Scientific Advisory Boardno data데이터 없음데이터 없음
Han Choi
Chief Financial Officerless than a year데이터 없음데이터 없음
Amy Quinlan
Interim Principal Accounting Officerless than a year데이터 없음0.042%
$ 22.7k
Tania Philipp
Chief People Officer4.9yrs데이터 없음데이터 없음
John King
Chief Commercial Officer & Head of Business Development4.3yrs데이터 없음데이터 없음
Samir Vattompadam
Senior Vice President of Portfolio Strategy & Program Management1.1yrs데이터 없음데이터 없음
David Phillips
Senior VP & Head of Quality1.1yrs데이터 없음데이터 없음

2.1yrs

평균 재임 기간

51yo

평균 연령

경험이 풍부한 관리: VOR 의 관리팀은 경험 ( 2.1 년 평균 재직 기간)으로 간주됩니다.


이사회 구성원

이름위치테뉴어보상소유권
Robert Ang
President5.3yrsUS$2.69m0.86%
$ 468.6k
Siddhartha Mukherjee
Scientific Founder & Chairman of Scientific Advisory Boardno data데이터 없음데이터 없음
David Lubner
Independent Director4.3yrsUS$151.60k0%
$ 0
Matthew Patterson
Independent Chairman of the Board4.1yrsUS$185.60k0.0088%
$ 4.8k
Joshua Resnick
Independent Director5.8yrsUS$157.50k0%
$ 0
Eric Sievers
Scientific & Clinical Advisorno data데이터 없음데이터 없음
Sven Lundberg
Independent Director5.7yrsUS$152.10k0.043%
$ 23.3k
Daniella Beckman
Independent Director4.3yrsUS$164.10k데이터 없음
Steven Devine
Scientific & Clinical Advisorno data데이터 없음데이터 없음
Robert Soiffer
Scientific & Clinical Advisorno data데이터 없음데이터 없음
Hans-Peter Kiem
Scientific & Clinical Advisorno data데이터 없음데이터 없음
Soheil Meshinchi
Scientific & Clinical Advisor3.8yrs데이터 없음데이터 없음

4.3yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 이사회: VOR 의 이사회경험(평균 재직 기간 4.3 년)으로 간주됩니다.